TRACON Pharmaceuticals (TCON) 10-K2022 FY Annual report

Filed: 8 Mar 23, 4:56pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: allegedly, Bristol, CAMT, chondrosarcoma, climate, contemporaneously, counter, coupled, culture, cybersecurity, dedifferentiated, degradation, Delinquent, difficulty, disbursed, disbursement, donut, doublet, downturn, energy, exacerbated, formula, gather, great, harvesting, hole, honor, ICC, infer, invasion, invoked, IRA, leiomyosarcoma, lender, lien, liposarcoma, macroeconomic, Obama, outpace, overdue, perfection, preemption, prepay, Prime, punitive, rarer, RCG, recession, recourse, reopened, repaid, retaliatory, RGC, Runway, science, shortly, talent, tightening, tranche, triplet, undergoing, undermine, unpaid, unresectable, variant, vi, vii, viii, voluntarily, Wall, weak, wider, widespread, wiretapping, workplace

Removed: acting, Ambrx, androgen, Aspire, borrow, Brown, bulletin, certified, compel, compensatory, complexity, compound, concurrently, constant, consultant, continuation, CPA, database, dated, delivering, determinable, dissolve, District, divided, duly, electronic, enhance, estate, fixed, inducing, Judge, kinase, LaRue, liquidate, long, Mark, Martin, Mattingly, media, men, minimize, mutant, NIK, OTC, personally, pharmacy, Pink, placement, protected, quotation, Rainer, refinance, returned, Scott, serving, sophistication, Stephen, subordinate, thereof, travel, Twiford, University, unlisted, virtue, William, Worland

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated TCON transcripts

TCON similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)Registration Statement (Form S-8 No. 333-263591) pertaining to the Amended and Restated 2015 Equity Incentive Plan and Amended and Restated 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,

(2)Registration Statement (Form S-8 No. 333-258077) pertaining to the Amended and Restated 2015 Equity Incentive Plan of TRACON Pharmaceuticals, Inc.,

(3)Registration Statement (Form S-8 No. 333-253546) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,

(4)Registration Statement (Form S-8 No. 333-236732) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,

(5)Registration Statement (Form S-8 No. 333-229988) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,

(6)Registration Statement (Form S-8 No. 333-223333) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,

(7)Registration Statement (Form S-8 No. 333-216347) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,

(8)Registration Statement (Form S-8 No. 333-209592) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,

(9)Registration Statement (Form S-8 No. 333-201808) pertaining to the 2011 Equity Incentive Plan, 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc.,

(10)Registration Statement (Form S-1 No. 333-239574) of TRACON Pharmaceuticals, Inc.,

(11)Registration Statement (Form S-1 No. 333-234651) of TRACON Pharmaceuticals, Inc.,

(12)Registration Statement (Form S-3 No. 333-263590) of TRACON Pharmaceuticals, Inc.,

(13)Registration Statement (Form S-3 No. 333-248593) of TRACON Pharmaceuticals, Inc., and

(14)Registration Statement (Form S-3 No. 333-224809) of TRACON Pharmaceuticals, Inc.

of our report dated March 8, 2023, with respect to the consolidated financial statements of TRACON Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2022.

/s/ Ernst & Young LLP

San Diego, California

March 8, 2023

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.